Due to high demand for its radiopharmaceutical for the treatment of tumors of neuroendocrine Lutter (Lutathera), the company and Novartis will build a second plant in the U.S., says FiercePharma.
When in 2017, Novartis has acquired the French company Advanced Accelerator Applications (AAA) for 3.9 billion dollars, no one could have predicted that the demand for a new drug of Lettera intended for the treatment of neuroendocrine tumors exceed the forecasts of analysts. A new plant in Indianapolis will work in 2023, the cost of the platform is not disclosed.
Lutter is a radiopharmaceutical that binds to somatostatin receptors on tumor cells, and then the drug enters the cell, targetirovanie exerting a destructive effect of radiation. A drug approved for the treatment of inoperable somatostatin-receptor positive neuroendocrine tumors of the gastrointestinal tract or the pancreas.
In 2019, sales of the drug exceeded Luttera 441 million dollars, net sales increased by 31% over the fourth quarter.